The Hill | September 3, 2021
“I do think that the White House will not have as smooth a path through the FDA as they think on boosters,” said Lawrence Gostin, a professor of global health law at Georgetown University Law.
“The scientific community is clearly not in lockstep behind them. President Biden got ahead of his public health agencies,” Gostin said.